Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Daré Bioscience Inc is a biotechnology business based in the US. Daré Bioscience shares (DARE) are listed on the NASDAQ and all prices are listed in US Dollars. Daré Bioscience employs 16 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $1.48 |
|---|---|
| 52-week range | $1.20 - $2.58 |
| 50-day moving average | $1.80 |
| 200-day moving average | $1.60 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.65 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.48 from 2022-01-26
| 1 week (2022-01-21) | -2.63% |
|---|---|
| 1 month (2021-12-28) | -26.00% |
| 3 months (2021-10-28) | 0.68% |
| 6 months (2021-07-28) | -1.33% |
| 1 year (2021-01-28) | -31.48% |
|---|---|
| 2 years (2020-01-27) | 19.35% |
| 3 years (2019-01-25) | 76.19% |
| 5 years (2017-01-27) | 85.00% |
| Gross profit TTM | $-83,333 |
|---|---|
| Return on assets TTM | -84.04% |
| Return on equity TTM | -246.51% |
| Profit margin | 0% |
| Book value | $0.42 |
| Market capitalisation | $121.8 million |
TTM: trailing 12 months
We're not expecting Daré Bioscience to pay a dividend over the next 12 months.
Daré Bioscience's shares were split on a 1:10 basis on 19 July 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Daré Bioscience shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Daré Bioscience shares which in turn could have impacted Daré Bioscience's share price.
Over the last 12 months, Daré Bioscience's shares have ranged in value from as little as $1.2 up to $2.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Daré Bioscience's is 1.3573. This would suggest that Daré Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Daré Bioscience, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.